Serina Therapeutics, Inc.
SERNYSEHealthcare · Pharmaceutical Preparations · AL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $130,000 | $56,000 | $3.2M | $34,000 | $144,000 | $361,000 |
| Operating income | −$24.0M | −$17.0M | −$3.1M | −$7.0M | −$7.9M | −$10.1M |
| Net income | −$19.2M | −$11.1M | $5.3M | −$10.5M | −$8.7M | $2.0M |
| Total assets | $7.0M | $6.7M | $9.0M | $3.2M | $3.2M | $3.9M |
| Total liabilities | $7.0M | $6.2M | $4.9M | $20.6M | $15.0M | $9.3M |
| Equity | −$37,000 | $641,000 | −$32.3M | −$17.2M | −$11.8M | −$5.1M |
| EPS (diluted) | $-1.91 | $-1.51 | $0.73 | $-9.70 | $-0.23 | — |
| Shares out. | 9.9M | 2.5M | 38.0M | 37.9M | 37.9M | 37.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −18478.5%
- Net margin
- −14755.4%
- Return on equity
- 51843.2%
- Return on assets
- −276.0%
- Return on capital (ROCE)
- −709.0%
- Liabilities / assets
- 100.5%
- Debt / equity
- —
- Book value / share
- $-0.00
- Revenue growth (YoY)
- 132.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -50.64distress
- Accruals / assets
- −17.7%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Sio Capital Management, LlcPassive (13G)May 4, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ledger Steven AOfficer — Chief Executive Officer | May 26, 2026 | Grant | 10,100 | $1.93 |
| Wilson Karen JDirector | May 21, 2026 | Buy | 10,000 | $1.77 |
| Marshall Richard PeterDirector | May 19, 2026 | Buy | 12,183 | $1.65 |
| Bailey GregoryDirector | Mar 31, 2026 | Grant | 59,667 | $1.94 |
| Venkatesan JayDirector | Mar 31, 2026 | Grant | 7,553 | $1.94 |
| Moreadith RandallOfficer — Chief Scientific Officer | Mar 23, 2026 | Option exercise | 6,500 | $0.06 |
| Moreadith RandallOfficer — Chief Scientific Officer | Mar 19, 2026 | Option exercise | 39,000 | $0.06 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 323,055 | 4.1 | +9.9% |
| Apr 30, 2026 | 293,855 | 4.1 | -21.4% |
| Apr 15, 2026 | 373,657 | 1.6 | -21.8% |
| Mar 31, 2026 | 478,077 | 1.0 | +332.6% |
| Mar 13, 2026 | 110,517 | 2.0 | -15.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Director / officer change · Amended charter or bylawsApr 21, 2026
- Results of operationsMar 25, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer change · Amended charter or bylaws · Regulation FD disclosureMar 23, 2026
- Other material eventJan 28, 2026
- Delisting / listing-standard notice · Regulation FD disclosureJan 15, 2026
- Other material eventDec 10, 2025
- Results of operationsNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spun off from BioTimeLCTX · Nov 28, 2018
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.